Is Restless Legs Syndrome Related to Parkinson’s?

Restless legs syndrome and Parkinson’s disease share enough surface-level features that clinicians and patients have debated a possible connection for decades, but the weight of evidence now points to two fundamentally different conditions that happen to involve some of the same brain chemistry. Both respond to drugs that boost dopamine activity, and people with Parkinson’s develop restless legs at roughly double the rate of the general population. Yet the deeper you look, the more the two conditions diverge: their genetics do not overlap, the hallmark brain pathology of Parkinson’s is absent in restless legs syndrome, and even the way each condition handles iron runs in opposite directions.

How Often the Two Conditions Overlap

Restless legs syndrome shows up in Parkinson’s patients far more often than in the general population, though estimates vary depending on how the studies are designed and where they are conducted. A systematic review pooling data from observational studies found that about 14% of people with Parkinson’s also met criteria for restless legs syndrome, compared to a significantly lower rate among matched healthy controls. The odds of a Parkinson’s patient having restless legs were nearly three times higher than for someone without Parkinson’s, and the condition was somewhat more common in women with Parkinson’s than in men.¹

A more recent meta-analysis, drawing on a total sample of nearly 7,000 Parkinson’s patients, put the pooled prevalence higher, at about 20%. That analysis also found that Parkinson’s patients with restless legs tended to have worse motor symptoms, more sleep disturbances, greater autonomic dysfunction, and more severe neuropsychiatric issues than those without restless legs.² So while having Parkinson’s does raise the likelihood of developing restless legs, it remains a minority of patients. And whether that higher rate reflects a shared underlying problem or simply arises from the medications and neurological disruption that come with Parkinson’s is where the story gets complicated.

Does Having Restless Legs Raise Your Risk of Developing Parkinson’s?

This question is probably the one people worry about most. If your legs won’t settle down at night, does that mean Parkinson’s could follow? The short answer: maybe a little, but the absolute risk is very small, and the connection is not straightforward.

A large matched cohort study that followed nearly 10,000 people with restless legs and the same number of controls found that about 1.6% of the restless legs group went on to develop Parkinson’s, compared to 1.0% in the control group.³ That is a real difference, but the absolute numbers are low enough that having restless legs is far from a reliable predictor. In practical terms, over 98% of the people with restless legs in that study did not develop Parkinson’s.

A separate study in a large cohort of men found that those with frequent restless legs symptoms had a higher risk of being diagnosed with Parkinson’s, but only when Parkinson’s appeared within the first four years of follow-up. The researchers framed this as evidence that severe restless legs might sometimes be an early feature of Parkinson’s itself rather than an independent risk factor, meaning the restless legs were potentially an early symptom of a disease process already underway.⁴ Another study using health-system data found that a diagnosis of restless legs was associated with roughly a twofold to threefold higher hazard of subsequent Parkinson’s, and this association persisted even after excluding cases diagnosed within the first year.⁵

These studies raise a genuine signal, but their design makes it hard to tell whether restless legs causes or contributes to Parkinson’s, or whether some people in the earliest, undiagnosed stages of Parkinson’s get labeled with restless legs first. The genetics data, covered below, strongly suggest the second interpretation.

The Dopamine Connection

The reason these two conditions keep getting lumped together is dopamine. Parkinson’s involves the progressive death of dopamine-producing neurons in a brain region called the substantia nigra, which leads to tremor, stiffness, and slowness of movement. Restless legs syndrome also responds dramatically to dopamine-boosting drugs, which led researchers to assume it must involve some kind of dopaminergic deficit too.

The reality is murkier. PET imaging has found that people with restless legs syndrome have reduced dopamine transporter binding in parts of the striatum, a brain region involved in movement.⁶ But an earlier SPECT imaging study directly comparing restless legs patients with early Parkinson’s patients and healthy controls found no difference in dopamine transporter binding between restless legs patients and controls, while early Parkinson’s patients showed a clear reduction. The researchers concluded there were “no common characteristics” between the two groups detectable by dopamine transporter imaging.⁷

A longitudinal study following Parkinson’s patients over four years added another wrinkle. Among those patients, the ones who developed restless legs actually had better dopaminergic transporter availability in the striatum than those who did not develop it. RLS prevalence in that cohort rose from under 5% at baseline to about 16% after four years, but the imaging suggested that the patients getting restless legs were not the ones with the worst dopamine depletion. The researchers proposed that neurotransmitter systems beyond dopamine are involved.⁸

So while both conditions involve dopamine, the nature of the dopaminergic disruption looks different. Parkinson’s is a story of neurons dying. Restless legs syndrome may be more about how dopamine is regulated at the cell surface than about cell loss, and other signaling systems probably play a role too.

Where the Biology Diverges

Two major biological differences make the case against a shared root cause. The first is iron. In Parkinson’s, iron accumulates excessively in the substantia nigra, contributing to oxidative stress and cell damage. In restless legs syndrome, the problem is the opposite: the brain appears to be relatively iron-deficient, and symptoms often improve when iron stores are replenished.⁹ Two conditions with opposite iron profiles are unlikely to share the same underlying disease mechanism.

The second difference is neuropathological. Parkinson’s disease is defined by the accumulation of clumps of alpha-synuclein protein, called Lewy bodies, in specific brain regions. When researchers examined brain tissue from people who had primary restless legs syndrome, they found no Lewy bodies and no alpha-synuclein pathology at all.¹⁰ If restless legs syndrome were an early form of, or a stepping stone toward, Parkinson’s, you would expect to find at least some trace of the same protein deposits. Their absence is telling.

Genetics Say the Two Are Unrelated

Perhaps the strongest evidence against a biological link comes from genetics. A study using Mendelian randomization, a technique that leverages naturally occurring genetic variation to test whether one condition causally influences another, found no genetic correlation whatsoever between restless legs syndrome and Parkinson’s disease. The genetic overlap was essentially zero.¹¹

Researchers have also looked at specific gene variants known to raise the risk of restless legs syndrome, including variants in genes called MEIS1, BTBD9, PTPRD, and MAP2K5/SKOR1, to see whether those same variants showed up more often in Parkinson’s patients with restless legs.¹² The gene variants linked to restless legs in the general population are distinct from those linked to Parkinson’s risk. The two conditions appear to run on separate genetic tracks, which makes a shared disease pathway unlikely even though both happen to involve dopamine signaling.

Why Telling Them Apart Can Be Tricky

Part of the reason the “are they related” question persists is that restless legs syndrome can look like several other things that are common in Parkinson’s. Akathisia, a feeling of inner restlessness and an urge to move, can occur as a side effect of certain medications or as a symptom of Parkinson’s itself. “Wearing-off” phenomena, where the benefit of a Parkinson’s medication fades before the next dose, can produce uncomfortable leg sensations. Painful neuropathy can mimic restless legs. And dystonia, involuntary muscle contractions, can produce leg discomfort at night. Studies have found that many Parkinson’s patients who initially report restless legs symptoms turn out, on closer examination, to have one of these mimics instead.¹³

There are clinical clues that help distinguish genuine restless legs syndrome from these look-alikes. Compared to people who have restless legs without any other neurological condition, Parkinson’s patients whose leg restlessness qualifies as true restless legs tend to have a later age of onset, a shorter history of symptoms, less family history of restless legs, and more one-sided symptoms that often match the side of the body more affected by their Parkinson’s.¹⁴ The one-sidedness is a useful clue: classic restless legs syndrome usually affects both legs, so a strongly asymmetric pattern in a Parkinson’s patient suggests the restlessness is driven by the Parkinson’s itself rather than by independent restless legs syndrome.

Parkinson’s patients with restlessness, whether it meets formal restless legs criteria or not, also tend to have more autonomic symptoms, worse sleep quality, and higher rates of depression.¹⁵ So the leg discomfort, while real and disruptive, often sits within a broader cluster of non-motor symptoms rather than being an isolated problem.

Treating Restless Legs in Someone Who Also Has Parkinson’s

Because both conditions respond to dopamine-boosting medications, there is real overlap in treatment. Dopamine agonists and levodopa can improve both Parkinson’s motor symptoms and restless legs. In practice, adjusting a Parkinson’s patient’s existing dopaminergic regimen is often the first step for managing restless legs that emerge alongside their Parkinson’s.¹⁶

The main treatment trap is a phenomenon called augmentation. Over time, dopaminergic medications, especially levodopa and short-acting dopamine agonists, can paradoxically make restless legs worse. Symptoms start earlier in the day, spread to other body parts, or become more intense. Current guidelines recommend using the lowest effective dopaminergic dose, favoring medications that deliver dopamine stimulation as smoothly and continuously as possible, and avoiding levodopa as the primary treatment for restless legs in Parkinson’s patients. For older patients, those with cognitive issues, or those who cannot tolerate dopamine agonists, a carefully dosed nighttime addition of levodopa can still be appropriate.¹⁶

Transdermal delivery of a dopamine agonist like rotigotine has been explored for both conditions, with the theoretical advantage that steady absorption through the skin might reduce the pulsatile stimulation that triggers augmentation and motor fluctuations.¹⁷ Longer-acting dopamine agonists like cabergoline have also shown efficacy in both Parkinson’s and restless legs, though the drug’s side-effect profile limits its use.¹⁸

Non-Dopaminergic Alternatives and Why They Matter

For restless legs specifically, a class of drugs called alpha-2-delta ligands, which includes gabapentin, gabapentin enacarbil, and pregabalin, has become increasingly important. These medications work through calcium channels rather than dopamine pathways. They are effective for restless legs and carry no known risk of augmentation, the worsening problem that plagues long-term dopamine-based treatment. The main side effects are drowsiness and dizziness.¹⁹

As evidence has accumulated that augmentation is specifically tied to dopaminergic drugs, gabapentinoids have moved toward being considered a safer initial treatment for restless legs in general.²⁰ This matters for the Parkinson’s overlap question because it highlights how the two conditions can be managed by completely different drug mechanisms. If restless legs were truly just an early form of Parkinson’s, you would not expect a calcium channel drug to work so well while leaving the Parkinson’s symptoms untouched. The effectiveness of non-dopaminergic treatments for restless legs reinforces the idea that the two conditions have different underlying mechanisms, even if dopamine is involved in both.

Deep Brain Stimulation and Restless Legs

Deep brain stimulation of the subthalamic nucleus, a surgical treatment used for advanced Parkinson’s disease, offers a unique window into how the two conditions interact. In a study of 36 Parkinson’s patients who received deep brain stimulation, 14 (about 39%) had restless legs beforehand. After surgery, restless legs resolved completely in about 43% of those who had them, and the remaining patients experienced at least some improvement. Meanwhile, two patients who had not previously had restless legs developed it after the procedure.²¹

The fact that stimulating a deep brain structure involved in motor circuits can relieve restless legs in some patients and trigger it in others suggests that the symptom is sensitive to changes in basal ganglia circuitry. It does not prove restless legs and Parkinson’s share a cause, but it does show that the neural networks affected by Parkinson’s can modulate restless legs symptoms, for better or worse.

Impulse Control Problems From Shared Medications

One underappreciated issue when dopamine agonists are used for restless legs is the risk of impulse control disorders. These are behavioral problems, including compulsive shopping, binge eating, gambling, and hypersexuality, that can emerge as side effects of dopaminergic medications. A case-control study of restless legs patients on dopamine agonist treatment found that about 17% developed at least one impulse control disorder. The rates were highest for compulsive eating and compulsive shopping, and there was a clear dose-response relationship with pramipexole, meaning higher doses brought higher risk.²²

This complication is well recognized in Parkinson’s disease, where dopamine agonists are used at higher doses and impulse control disorders are a frequent clinical concern. Restless legs patients generally take lower doses, but the risk is not zero. For someone managing both conditions, the total dopaminergic load can push the impulse control risk higher. This is another reason clinicians are increasingly cautious about using dopamine agonists as the default treatment for restless legs, especially in patients who are already taking dopaminergic drugs for Parkinson’s, and why the gabapentinoid alternatives have gained ground.

Iron Replacement as a Distinguishing Treatment

Because restless legs syndrome is linked to relative brain iron deficiency, checking ferritin levels and supplementing iron when stores are low is a standard part of restless legs management. Guidelines generally recommend targeting a ferritin level above a certain threshold before escalating to other medications. Many patients see meaningful symptom improvement simply from iron supplementation, whether taken orally or given intravenously when oral forms are not absorbed well enough.

In Parkinson’s disease, by contrast, iron accumulation in the substantia nigra is part of the problem. Giving extra iron to a Parkinson’s patient would not be expected to help their motor symptoms, and there has been exploratory interest in iron chelation therapy to reduce iron-driven oxidative stress in Parkinson’s.⁹ The two conditions respond to iron manipulation in opposite directions, which is hard to square with a shared pathology. For a Parkinson’s patient who also has restless legs, iron supplementation may still help the restless legs component, since that symptom appears to arise from a different mechanism than the Parkinson’s itself. But the iron story is one of the clearest illustrations that what looks like a single overlap on the surface conceals two very different biological realities underneath.